Zhongda'an: Wu Junye, the controlling shareholder, plans to reduce his holdings by no more than 2%

Big Pharma CCHT’s Domination Unlikely to Fade Soon Despite Official Bulk Buying

The producer of long-acting growth hormone acupunctures, vaccines and other drugs, looks set to offset the effects of so-called “centralized procurement” on its product prices with more aggressive expansion into private hospitals. So far, its monopoly appears unshakable, but with more competitors upping the stakes, how long will it last?

Week's Go Global Information Gap (11/23–11/29): The US launched the AI "Genesis Project"

Amid fast-paced changes that fill the business community with excitement, angst and trepidation, EqualOcean will publish a series of roundup articles to document the major events related to Chinese companies going global every week.

China and U.S. Agree to Pause Certain Tariffs and Export Restrictions

​On October 30, China’s Ministry of Commerce (商务部) officially released the outcomes of the China–U.S. trade consultations held in Kuala Lumpur. Building on the consensus reached during the China–U.S. presidential meeting in Busan, the two countries’ economic and trade teams achieved substantive breakthroughs on key issues such as tariffs and export controls, providing a strong boost of confidence to the global economy.

QCraft Debuts at Japan Mobility Show, Starts L4 Robobus Commercial Deployment in Japan

QCraft debuted at the 2025 Japan Mobility Show (49th Tokyo Motor Show), presenting its first mature L4 autonomous products for Japan — the Robobus and its full-stack autonomous driving solution — signaling the start of its commercial rollout in the country.

The Overlooked 120 Million Consumers

Japan is a demanding but high-value market. Chinese sellers are growing fast, yet success requires more than low prices—clear manuals, strong quality, 24/7 service, and trust. Consumption is polarizing, and aging buyers remain active. Long-term branding and localization are key.